COPD & Emphysema Support Group
COPD is a progressive disease characterized by airflow obstruction or limitation. Emphysema is characterized by loss of elasticity of the lung tissue, destruction of structures supporting the alveoli and of capillaries feeding the alveoli. Both have symptoms that include shortness of breath, among other respiratory troubles. If you are a COPD or Emphysema sufferer, join...
I am not sure you can take what's published by a malpractice attorney at face value. The FDA (Food & Drug Administration) may not be perfect, but I think they are a more reliable source for information.
Advair is in a drug class called Long-Acting Beta-Agonist or LABAs. Other drugs in the class include Foradil, Symbicort and Serevent.
The FDA modified their prescribing recommendations for LABAs back in February for asthma patients, but said "FDA has determined that the benefits of LABAs in improving asthma symptoms outweigh the potential risks when used appropriately with an asthma controller medication in patients who need the addition of LABAs"
The FDA also said "There is no evidence to conclude that people with C-O-P-D who use LABAs are at any greater risk compared to people with C-O-P-D who do not use LABAs. FDA does not recommend any change in the use of LABAs for C-O-P-D".
Hugs,
TJ
The FDA approving these drugs doesn't change the results of many clinical trials and cold hard facts!